Skip to main content

Table 1 Different tumors and tracers in neuro-oncology for different indications: target delineation (TD), prognostication (P), distinguishing between progressive disease and pseudoprogression (TR)

From: Recent advances of PET imaging in clinical radiation oncology

Tumor entity

Tracers

Indication

Comment

Glioma

18F-FET

TD/P/TR

Valuable as longer halftime compared to 11C-MET, high diagnostic accuracy with histopathological validation; ongoing trials to confirm clinical benefit, e. g. GLIAA [25]

18F-DOPA

TD/P/TR

Studies on prognostic relevance and histopathological validation available, e.g. [24, 26], mainly used in the US

11C-MET

TD/P

Studies on prognostic relevance and histopathological validation available. Aiding in target delineation.

TSPO ligands

None

Investigational, no histopathological validation studies (ongoing)

Meningioma

68Ga-DOTATOC

TD

Aiding in target delineation or surgical approach, especially when located at the skull base

68Ga-DOTATATE

TD

SUV cutoff histologically validated, no relevant data available on response

Brain metastasis

18F-FET

TR

Differentiation pseudoprogression/radiation necrosis vs. tumor recurrence

CNS lymphoma

18F-FDG

None

Tumor metabolism, response assessment [27]